deferasirox has been researched along with Diabetic Nephropathies in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hitomi, H; Ichihara, A; Kitada, K; Kobori, H; Morimoto, S; Morita, T; Nakano, D; Nishiyama, A; Shiojima, I | 1 |
1 other study(ies) available for deferasirox and Diabetic Nephropathies
| Article | Year |
|---|---|
Chelation of dietary iron prevents iron accumulation and macrophage infiltration in the type I diabetic kidney.
Topics: Animals; Benzoates; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; Deferasirox; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Gene Knockout Techniques; Iron; Iron Chelating Agents; Iron, Dietary; Kidney; Macrophages; Male; Mice; Mice, Inbred C57BL; Triazoles | 2015 |